SNYR Synergy CHC Corp.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $27.7M and net income of −$15.8M.
SNYR revenue and earnings
- Quarter ended Mar 31, 2026: revenue $5.49M, net income −$2.57M, EPS -0.23
- Quarter ended Dec 31, 2025: revenue $6.07M, net income −$14.8M, EPS -1.55
- Quarter ended Sep 30, 2025: revenue $8.01M, net income $125K, EPS 0.01
- Quarter ended Jun 30, 2025: revenue $8.13M, net income $1.47M, EPS 0.17
Recent SNYR insider trades
- Jul 30, 2025: Ross Jack bought 27,900 shares ($79.6K)
- Jun 10, 2025: Ross Jack bought 16,100 shares ($29.8K)
- May 15, 2025: Ross Jack bought 5,300 shares ($10.9K)
- Apr 10, 2025: Ross Jack bought 14,340 shares ($39.4K)
5%+ owners
- KNIGHT THERAPEUTICS INC.: 19.9% (Schedule 13G/A, filed Jun 13, 2025)
Are insiders buying or selling SNYR?
No open-market insider buys or sells of Synergy CHC Corp. were reported in the last 12 months.
What was SNYR's revenue last quarter?
Synergy CHC Corp. reported revenue of $5.49M for the quarter ended March 31, 2026, with net income of −$2.57M.